$Overall survival by IDH2 mutant allele (R140 or R172) in patients with late-stage mutant- IDH2 relapsed or refractory acute myeloid leukemia treated with enasidenib or conventional care regimens in the phase 3 IDHENTIFY trial$

Overall survival by IDH2 mutant allele (R140 or R172) in patients with late-stage mutant- IDH2 relapsed or refractory acute myeloid leukemia treated with enasidenib or conventional care regimens in the phase 3 IDHENTIFY trial

Xehetasun bibliografikoak
Egile Nagusiak:	De Botton, S, Risueño, A, Schuh, AC, Lowenberg, B, Kim, H-J, Vyas, P, Wei, AH, Stein, EM, Dohner, H, Fathi, AT, Dinardo, CD, Martin Regueira, P, Taningco, L, Bluemmert, I, Yu, X, See, WL, Hasan, M
Formatua:	Conference item
Hizkuntza:	English
Argitaratua:	American Society of Clinical Oncology 2022

Deskribapena
Gaia:

Overall survival by IDH2 mutant allele (R140 or R172) in patients with late-stage mutant- IDH2 relapsed or refractory acute myeloid leukemia treated with enasidenib or conventional care regimens in the phase 3 IDHENTIFY trial

Antzeko izenburuak